TRDA NASDAQ
Entrada Therapeutics, Inc.
1W: -12.7%
1M: -26.3%
3M: -28.6%
YTD: -46.5%
1Y: -8.5%
3Y: -65.3%
$5.38
-0.30 (-5.28%)
Weekly Expected Move ±9.6%
$4
$5
$5
$6
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-12-08
Earliest Filing
2023-11-01
Latest Filing
partner: 3
Counterparties (Filed by TRDA)
3 relationshipsCompanies named in TRDA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | partner | Amendment to Strategic Collaboration and License Agreement and Sublicense Agreement | 2023-11-01 | View |
| Cowen and Company, LLC | — | partner | Entrada Therapeutics, Inc. entered into a sales agreement with Cowen and Company, LLC to act as Sales Agent for an at-th | 2023-09-29 | View |
| Vertex Pharmaceuticals Incorporated | VRTX | partner | Strategic collaboration and license agreement for ENTR-701 development and commercialization, plus equity investment. | 2022-12-08 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-10 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-19 | Regulation FD; Exhibits | View | |
| 2026-05-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-03 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-05-08 | Results of Operations and Financial Condition | View | |
| 2025-04-29 | Costs Associated with Exit or Disposal Activities | View | |
| 2025-03-24 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-24 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-02-03 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-01-15 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-24 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-06-24 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR